Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Myogen: Cure for an aching heart

Myogen Inc. is combining the pursuit of a near-term product opportunity in cardiovascular disease with its expertise in advanced heart failure to develop drugs based on the molecular understanding of the disease.

CEO William Freytag said the company was born out of the founders' vision to "define the molecular basis of heart failure." The initial company was more of an academic collaboration than a profit-driven enterprise, he said.

According to Freytag, a strategy for financial

Read the full 737 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers